The site, which is expected to be ready for media fill by the end of 2029, is meant to strengthen the CDMO’s aseptic manufacturing capabilities in early clinical development.
The expansion in Plano includes 5,000 square feet of new laboratory space and doubling its Good Manufacturing Practice production capacity for early clinical trial supply.
